Cargando…

Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis

BACKGROUND: Cancer therapy has evolved from non-specific cytotoxic agents to a selective, mechanism-based approach that includes targeted agents and immunotherapy. Although the response to targeted therapies for unresectable hepatocellular carcinoma (HCC) is acceptable with the improved survival, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Teng-Kai, Yu, Ya-Fang, Tsai, Chiao-Ling, Li, Hsing-Ju, Yang, Po-Sheng, Huang, Kai-Wen, Cheng, Jason Chia-Hsien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587661/ https://www.ncbi.nlm.nih.gov/pubmed/36271374 http://dx.doi.org/10.1186/s12885-022-10174-6

Ejemplares similares

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma
por: Liu, Wei-Lin, et al.
Publicado: (2014)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
por: Kumar, Shashank, et al.
Publicado: (2023)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy
por: Chen, Yi-Lun, et al.
Publicado: (2022)

Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity
por: Tsai, Chiao-Ling, et al.
Publicado: (2023)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
por: Singal, Amit G., et al.
Publicado: (2022)

Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis
por: Liu, Kun, et al.
Publicado: (2023)

Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report
por: Feng, Yu-Min, et al.
Publicado: (2021)

Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
por: Guo, Tao, et al.
Publicado: (2019)

Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm
por: Su, Ting-Shi, et al.
Publicado: (2016)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma
por: Que, Jenny, et al.
Publicado: (2016)

Targets of immunotherapy for hepatocellular carcinoma: An update
por: Rai, Vikrant, et al.
Publicado: (2022)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
por: Su, Chung‐Wei, et al.
Publicado: (2022)

Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China
por: Li, Jieying, et al.
Publicado: (2022)

Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy
por: Zheng, Hongyu, et al.
Publicado: (2023)

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Li, Weiwei, et al.
Publicado: (2022)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy
por: Navadurong, Huttakan, et al.
Publicado: (2023)

Hepatic Arterial Infusion Chemotherapy for Patients with Huge Unresectable Hepatocellular Carcinoma
por: Tsai, Wei-Lun, et al.
Publicado: (2014)

Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma
por: Hsiao, Chih-Yang, et al.
Publicado: (2020)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Computed Tomography-Defined Sarcopenia in Outcomes of Patients with Unresectable Hepatocellular Carcinoma Undergoing Radioembolization: Assessment with Total Abdominal, Psoas, and Paraspinal Muscles
por: Wu, Chih-Horng, et al.
Publicado: (2023)

The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma
por: Yang, Zhi-Wen, et al.
Publicado: (2018)

A Case of Streptozocin Monotherapy for Unresectable Duodenal Neuroendocrine Tumor G2
por: Miyagawa, Koji, et al.
Publicado: (2019)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018)

Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2021)

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
por: Laface, Carmelo, et al.
Publicado: (2023)

Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells
por: Tien, Yun, et al.
Publicado: (2020)

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

The ratio of weight loss to planning target volume significantly impacts setup errors in nasopharyngeal cancer patients undergoing helical tomotherapy with daily megavoltage computed tomography
por: Hou, Wei-Hsien, et al.
Publicado: (2016)

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
por: Stack, Anthony, et al.
Publicado: (2019)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Platinum versus immunotherapy for unresectable esophageal cancer: A protocol for systematic review and meta analysis
por: Qian, Jiekun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kcvj3sdho8sn6ie7hsmoc118nu